Breaking Finance News

Shire PLC (ADR) (NASDAQ:SHPG) has been upgraded to Buy in a statement by ValuEngine earlier today.

ValuEngine has upgraded Shire PLC (ADR) (NASDAQ:SHPG) to Buy in a statement released on 07/06/2017.

Having a price of $169.33, Shire PLC (ADR) (NASDAQ:SHPG) traded -0.91% lower on the day. With the last stock price up 0.00% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.05% over the same period. SHPG has recorded a 50-day average of $0.00 and a two hundred day average of $0.00. Trade Volume was up over the average, with 958,069 shares of SHPG changing hands over the typical 0

Recent Performance Chart

Shire PLC (ADR) (NASDAQ:SHPG)

Shire PLC (ADR) has with a one year low of $147.79 and a one year high of $209.22 and has a market capitalization of $0.

A total of 14 brokerages have issued a ratings update on Shire PLC (ADR). Seven brokerages rating the company a strong buy, seven brokerages rating the company a buy, two brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $241.86.

General Company Details For Shire PLC (ADR) (NASDAQ:SHPG)

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *